Trial summary: This study will investigate whether sacituzumab tirumotecan (MK-2870) alone or with chemotherapy can treat certain gastrointestinal (GI) cancers, including advanced pancreatic cancer.
Status: CLOSED - Not Recruiting
Trial identifier: NCT06428409
Sponsor: MSD
Phase: I/II
Diagnosis: Metastatic (Stage IV) pancreatic ductal adenocarcinoma
Line of therapy: Second-line
Treatment: TROP2 inhibitor MK-2870 monotherapy or in combination with chemotherapy
  • Key inclusion criteria

    The main inclusion criteria include but are not limited to the following:

    • Has one of the following cancers:
      • Unresectable or metastatic colorectal cancer
      • Advanced or metastatic pancreatic ductal adenocarcinoma (PDAC)
      • Advanced and/or unresectable biliary tract cancer (BTC)
    • Has received prior therapy for the cancer
    • Has recovered from any side effects due to previous cancer treatment
  • Key exclusion criteria

    The main exclusion criteria include but are not limited to the following:

    • History of severe eye disease
    • Received prior systemic anticancer therapy, including investigational agents, within 4 weeks before starting study intervention
    • History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease

MK9999

Locations: Epworth Richmond, Epworth Freemasons (East Melbourne), Epworth Eastern (Box Hill).

Epworth PI: A/Prof Sumitra Ananda

Jreissati Pancreatic Centre at Epworth 

Access this Clinical Trial

Healthcare professionals


Refer your patient

General enquiries

Please contact us for more information on 03 9426 8880 or email [email protected]


Back to all Clinical Trials and Research Studies